Loading...
Keywords
Last Name
Institution

Connection

Search Results to J. Steven Leeder

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Leeder, J. Steven

PropertyValue
research overview In his former role as Director of the Division of Clinical Pharmacology and Therapeutic Innovation at Children’s Mercy Dr. Leeder led a program consisting of multidisciplinary teams of researchers with expertise in analytical chemistry, drug biotransformation, gene regulation, pharmacogenomics, and pharmacokinetics to investigate variability in medication response in children. An important component of the program was to provide an environment in which trainees and early career faculty members from diverse backgrounds could develop as independent investigators in their areas of research interest. These research interests generally are closely aligned with their clinical expertise with the goal of implementing precision therapeutics in their clinical subspecialties to benefit the patients they serve. Currently, Dr Leeder is Executive Director (Interim) of the Children’s Mercy Research Institute and leads the Precision Therapeutics Area of Emphasis. The Precision Therapeutics initiative extends the Division of Clinical Pharmacology's emphasis on developing individuals to a more institutional level by providing support to pediatric subspecialties interested in adding precision therapeutics to their portfolio of research programs. In this way the program serves as a model of integrated research that will extend throughout the CMRI. Over the years, Dr. Leeder's research interests in pediatric pharmacogenetics and the ontogeny of drug biotransformation pathways during growth and development have coalesced into the GOLDILOKs initiative: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids. Originally funded as one of four Specialized Centers for Research in Pediatric Developmental Pharmacology supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development, "GOLDILOKs" now represents a conceptual approach to better understanding factors contributing to variability in drug disposition and response and using that information to make the use of medications safer and more effective in children of all ages. Dr. Leeder is also co-PI, with Dr. Mario Castro (KUMC), of the Frontiers Clinical and Translational Science Institute at the University of Kansas.

One or more keywords matched the following items that are connected to Leeder, J. Steven

Item TypeName
Concept Biotransformation
Academic Article Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Academic Article Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
Academic Article Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites.
Academic Article Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro.
Academic Article Ontogeny of drug metabolizing enzymes in the neonate.
Academic Article Variability of CYP3A7 expression in human fetal liver.
Academic Article Biotransformation of fluticasone: in vitro characterization.
Academic Article Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants.
Academic Article Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.
Academic Article Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.
Academic Article Identifying genomic and developmental causes of adverse drug reactions in children.
Academic Article Pharmacogenetics in pediatrics. Implications for practice.
Academic Article Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children.
Academic Article VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Academic Article Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Academic Article Variability in Expression of CYP3A5 in Human Fetal Liver.
Academic Article Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.
Academic Article In Vitro Hepatic Oxidative Biotransformation of Trimethoprim.
Academic Article Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
Academic Article Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
Academic Article Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.
Academic Article Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.
Academic Article Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.
Academic Article Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs.
Academic Article The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites.
Academic Article The Impact of Age and Genetics on Naltrexone Biotransformation.
Grant Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology

Search Criteria
  • Biotransformation